LKT Labs

Biochemicals for Life Science Research

Canertinib Dihydrochloride

Canertinib Dihydrochloride

Product ID C0252
Cas No. 289499-45-2
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $134.70 Please Inquire
100 mg $404.30 In stock
250 mg $808.60 In stock
Bulk Quote

Quicklinks

Description

Canertinib is an irreversible inhibitor of EGFR (HER2/ErbB). This compound is currently in clinical trials as an anticancer chemotherapeutic, displaying activity against a variety of cancers. In a cellular model of melanoma, canertinib exhibits cytostatic activity, stopping cell growth in the G1 phase, but not inducing apoptosis except at very high concentrations. In a related animal model, canertinib inhibits tumor growth. Separately, canertinib inhibits Akt and ERK1/2 in cells lacking ErbB receptors and induces caspase-mediated apoptosis.

Product Info

Cas No.

289499-45-2
Purity

≥98%
Formula

C24H25ClFN5O3 • 2HCl
Formula Wt.

558.86
Chemical Name

N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6- yl]prop-2-enamide;dihydrochloride
IUPAC Name

N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6- yl]prop-2-enamide;dihydrochloride
Synonym

CI1033
Appearance

Pale yellow powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

C0252 MSDS PDF
Info Sheet

C0252 Info Sheet PDF
Brochures

PI3K-Akt-mTORC Pathway Booklet

Ras-Raf-MEK-ERK Pathway Booklet

References

Djerf Severinsson EA, Trinks C, Gréen H, et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011 Oct 28;414(3):563-8. PMID: 21982771.

Trinks C, Severinsson EA, Holmlund B, et al. The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells. Biochem Biophys Res Commun. 2011 Jul 8;410(3):422-7. PMID: 21669187.

Zinner RG, Nemunaitis J, Eiseman I, et al. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res. 2007 May 15;13(10):3006-14. PMID: 17505003.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S8169

    Suramin Hexasodium

    RyR agonist, SIRT, telomerase, P2Y, GPCR inhibi...

    ≥98%
  • E5201

    Enalapril Maleate

    ACE inhibitor.

    ≥98%
  • S4932

    SMI-4a

    Thiazolidine; Pim kinase inhibitor.

    ≥99%
  • O2144

    Ofloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • I0481

    Ibuprofen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • P2919

    L-Phenylalaninol

    Non-essential amino acid alcohol.

    ≥98%
  • A4849

    Amyloid-β (25-35)

    Endogenous APP peptide cleavage product, primar...

    ≥95%
  • C1632

    Cefotaxime Acid

    β-lactam cephalosporin; penicillin binding pro...

    ≥91%
  • B6856

    5-Bromo-2′-Deoxyuridine

    Nucleoside (thymidine) analog.

    ≥98%
  • T5869

    Torcetrapib

    Cholesterol ester transfer protein inhibitor.

    ≥98%
  • R5773

    Rosiglitazone

    Thiazolidinedione; PPARγ agonist.

    ≥99%
  • T8145

    Tulobuterol Hydrochloride

    β2-adrenergic agonist.

    ≥98%
  • R3249

    Rimantadine Hydrochloride

    Viral M2 proton channel blocker.

    ≥98%
  • L5751

    Lomerizine Dihydrochloride

    L-type and T-type Ca2+ and TRP antagonist.

    ≥98%
  • P8118

    Puerarin

    Isoflavone daidzein derivative found in Puerari...

    ≥96%
  • L4796

    LY-294002

    PI3K inhibitor.

    ≥99%
  • C3208

    Ciclopirox Olamine

    Hydroxypyridone, metal ion chelator; mTOR inhib...

    ≥98%
  • R0109

    Racecadotril

    Enkephalinase inhibitor.

    ≥98%
  • M5675

    Motilin, canine

    Endogenous peptide hormone; motilin agonist.

    ≥95%
  • R2815

    Recombinant HIV-1 “0” group consensus

    Recombinant HIV-1 antigen fragment.

    ≥95%